• Climb Bio posted a GAAP net loss of USD 13.5 million, widening from USD 8.67 million a year earlier.
• R&D expense rose to USD 9.71 million from USD 6.58 million; G&A expense increased to USD 5.65 million from USD 4.1 million.
• Cash, cash equivalents, and marketable securities climbed to USD 239.22 million as of June 30, 2026, from USD 160.65 million at end-2025.
• Private placement financing generated about USD 110 million in gross proceeds, extending cash runway into the second half of 2028.
• CLYM116 Phase 1 PK/PD data due at an R&D Spotlight on Sept. 3; Phase 2 IgA nephropathy dosing expected to start in Q3 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.